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Abstract: Oridonin, a diterpenoid isolated from Rabdosia rubescencs, has been reported to 
have antitumor effects. However, low solubility has limited its clinical applications.   Preparation 
of drugs in the form of nanosuspensions is an extensively utilized protocol. In this study, we 
investigated the anticancer activity of oridonin and oridonin nanosuspension on human pancreatic 
carcinoma PANC-1 cells. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay 
was performed to investigate the effect of oridonin on cell growth. Propidium iodide and Hoechst 
33342 staining were used to detect morphologic changes. The percentage of apoptosis and cell 
cycle progression was determined by flow cytometric method staining with propidium iodide. 
Annexin V-fluorescein isothiocyanate (FITC)/PI staining was used to evaluate cell apoptosis by 
flow cytometry. Caspase-3 activity was measured by spectrophotometry. The apoptotic and cell 
cycle protein expression were determined by Western blot analysis. Both oridonin and oridonin 
nanosuspension induced apoptosis and G2/M phase cell cycle arrest, and the latter had a more 
significant cytotoxic effect. The ratio of Bcl-2/Bax protein expression was decreased and cas-
pase-3 activity was stimulated. The expression of cyclin B1 and p-cdc2 (T161) was   suppressed. 
Our results showed that oridonin nanosuspension was more effective than free oridonin on G2/M 
cell cycle arrest and apoptosis in the human pancreatic cancer PANC-1 cell line.
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Introduction
Oridonin (Figure 1), an active diterpenoid isolated from the herb Rabdosia rubescens, 
which is often used in Chinese traditional medicine, has been reported to have antitumor 
activities.1–3 Previous studies demonstrated that oridonin exhibited remarkable inhibi-
tory effects on tumor cell proliferation and was a potent apoptosis inducer in a variety 
of cancer cells by regulating a series of transcription factors, protein kinases, as well as 
pro- and/or anti-apoptotic proteins.4–7 Accumulating evidence has shown that oridonin 
is able to block the progression of tumors and alleviate cancer syndrome, which may 
improve the survival rates of cancer patients greatly, suggesting that oridonin may be 
used as a potential antineoplastic drug for future cancer therapeutics. However, studies 
on the effects of oridonin on human pancreatic cancer are limited. Pancreatic carcinoma 
is one of the most common causes of cancer death. It is a fast-developing disease which 
is difficult to detect and diagnose and often has a poor prognosis.8,9 Therefore, adjuvant 
therapy, especially chemotherapy, to improve the quality of life for advanced pancreatic 
cancer patients is increasingly important. In this study, we investigated the anticancer 
activity of oridonin on human epithelial-like pancreatic cancer cell line PANC-1, which 
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is used as an in vitro model of nonendocrine pancreatic cancer 
for tumorigenicity studies.
Furthermore, low aqueous solubility and/or dissolution of 
oridonin and short biological half-life in vivo have limited its 
medical applications as a therapeutic agent. Therefore, it is 
critical to develop new strategies for overcoming this prob-
lem. The preparation of drugs in the form of nanosuspensions 
has been shown to be an extensively utilized protocol to tackle 
the problems of insoluble compounds.10,11   Nanosuspensions 
are suspensions of drug nanocrystals in a liquid stabilized by a 
surfactant or polymer. With small particle size and enormous 
particle surface, nanosuspensions increase the solubility 
and dissolution velocity, and consequently improve drug 
bioavailability. Besides, nanosuspension can also produce 
bioadhesion, increase   stability, and enhance cytotoxicity 
of the agents.12 In previous   studies, we prepared the stable 
oridonin nanosuspension by high-pressure homogeniza-
tion, which resulted in increased drug saturation solubility 
and dissolution velocity.13 In vitro experiments showed that 
oridonin nanosuspension could significantly enhance cyto-
toxicity against K562 cells and induce a higher apoptotic 
rate in K562 cells compared to the oridonin   solution. In 
vivo studies in a mouse model of sarcoma-180 solid tumors 
demonstrated significantly greater inhibition of tumor growth 
following treatment with oridonin nanosuspension than with 
oridonin solution at the same   dosage. These results sug-
gest that the delivery of oridonin as a nanosuspension is a 
promising approach for the treatment of tumors.14   Therefore, 
in this study, we investigated the anticancer activity of ori-
donin nanosuspension on human pancreatic cancer cell line 
PANC-1 compared with free oridonin.
Materials and methods
Materials
Oridonin  (99%  pure  by  high  performance  liquid 
chromatography) was obtained from Shanxi Huike Plants 
  Exploitation (Xian, China). Oridonin and oridonin nanosus-
pension   solution were prepared as described previously;15 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) and dimethyl sulfoxide were purchased from 
Sigma-Aldrich (St Louis, MO). Fetal bovine serum was 
purchased from TBD Biotechnology Development (Tianjin, 
China). Trypsin was purchased from Gibco BRL (Gaith-
ersburg, MD). Propidium iodide (PI), ribonuclease A, and 
annexin V-FITC were purchased from KeyGen Biotechnol-
ogy   (Nanjing, China). Antibodies against Bax, Bcl-2, cas-
pase-3, and β-actin and horseradish peroxidase-conjugated 
secondary antibody (goat-anti-rabbit or goat-anti-mouse) 
were procured from Santa Cruz Biotechnology (Santa Cruz, 
CA); antibodies against cyclin B1, cdc2, and p-cdc2 (T161) 
were procured from Bioworld Technology (Minneapolis, 
MN). All other chemicals were of analytical grade.
Cell culture
Human pancreatic cancer cell line PANC-1 cells were 
cultured in DMEM supplemented with 10% newborn calf 
serum, 100 U/mL penicillin, and 100 µg/mL streptomycin, 
and were maintained at 37°C with 5% CO2 in a humidified 
atmosphere. All the experiments were performed on loga-
rithmically growing cells.
Cell viability assay
The viability of cells treated with oridonin nanosuspension 
or free oridonin was measured by MTT assay. Cells were 
suspended at a final concentration of 5 × 104 cells/well and 
cultured in a 96-well flatbottomed microplate. After 12 hours’ 
incubation, the cells were treated with oridonin nanosus-
pension or free oridonin (1.56, 3.14, 6.25, 12.5, 25, and 
50 µmol/L) for 12 hours, 24 hours, 36 hours, and 48 hours. 
At the end of the treatment, 20 µL MTT solution (5 mg/mL) 
was added to each well and the cells were then incubated for 
4 hours. The culture media were then replaced with 150 µL 
dimethyl sulfoxide. Light absorbance of the solution was mea-
sured at 570 nm on a Bio-Rad Model 680 microplate reader 
(Hercules, CA). The cell inhibitory rate was calculated as 
follows: Inhibitory rate = (A570 control cells – A 570 treated cells)/A570 control 
cells × 100%. All assays were done with six parallel samples.
Observation of morphologic changes
PANC-1 cells were seeded in six-well culture plates 
and treated with different concentrations of oridonin 
  nanosuspension or free oridonin for 24 hours. Then the cel-
lular morphologic changes were observed.
hoechst 33342 and PI staining
Cells were seeded onto a 12-well plate and incubated with 
oridonin nanosuspension or free oridonin for 24 hours. 
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Figure 1 The chemical structure of oridonin.
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  Following the incubation period, the cells were stained with 
1 µg/mL Hoechst 33342 for 30 minutes in the dark. For PI 
staining, after treatment cells were harvested and washed with 
phosphate-buffered saline (PBS). Aliquots of cell suspen-
sion (95 µL; 1 × 106 cells/mL) were mixed with 5 µL PI and 
incubated in the dark for 5 minutes. Stained cells were then 
imaged under a Nikon TE2000-U fluorescent microscope 
(Tokyo, Japan).
Cell cycle assay by flow cytometric 
analysis
PANC-1 cells treated with oridonin nanosuspension or free ori-
donin for different time periods were harvested, washed with 
PBS, and fixed in 75% ethanol overnight at 4°C. Prior to analy-
sis, cells were washed again with PBS, resuspended and treated 
with ribonuclease A 0.25 mg/mL for 30 minutes at 37°C, then 
incubated with 20 mg/L PI in the dark for 30 minutes. Then 
the samples were analyzed by flow cytometer.
Evaluation of apoptosis
To quantify the apoptosis of cells treated with oridonin 
nanosuspension or free oridonin, annexin V-FITC/PI stain-
ing was performed, and apoptosis was evaluated by flow 
cytometric analysis. PANC-1 cells were exposed to different 
concentrations of oridonin nanosuspension or free oridonin 
for 24 hours. After treatment, 1 × 105 cells were collected, 
washed twice with PBS, and resuspended in 500 µL binding 
buffer. Later, 5 µL of annexin V-FITC and 5 µL of PI were 
added to the suspension and the cells were then incubated in 
the dark for 15 minutes at room   temperature. Samples were 
then analyzed by flow cytometer.
Caspase-3 activity assay
PANC-1 cells were cultured with 10 µmol/L oridonin nano-
suspension or free oridonin for different time periods (4 hours, 
8 hours, 12 hours, and 24 hours). The activity of caspase-3 was 
detected by cleavage of chromogenic caspase-3 substrates, 
Ac-DEVD-pNA (acetyl-Asp-Glu-Val- Asp p-nitroanilide). 
Protein was extracted using ice-cold cell lysis buffer and 
approximately 100 µg of total protein was added to reaction 
buffer containing Ac-DEVD-pNA (2 mM), incubated over-
night at 37°C. The free pNA cleaved from its precursor can 
be quantified using a spectrometer at 405 nm.
Western blot analysis
The PANC-1 cells treated with oridonin nanosuspension or 
free oridonin for different time periods were collected, washed 
with ice-cold PBS, and resuspended in lysis buffer containing 
50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% 
sodium deoxycholate, 0.1% sodium dodecyl sulfate, sodium 
orthovanadate, sodium fluoride, ethylenediaminetetraacetic 
acid, and leupeptin. After 30 minutes of incubation on ice, the 
lysate was centrifuged at 12,000 g for 10 minutes and the super-
natants were used for Western blot analysis. Protein concentra-
tion was determined by bicinchoninic acid assay. Equal amounts 
of total protein were separated by 12% gel electrophoresis and 
electrophoretically transferred to nitrocellulose membranes. 
Immunoblotting was performed with different antibodies and 
visualized using an enhanced chemiluminescence method.
Statistical analysis
The results are expressed as the mean ± standard deviation. 
Statistical significance of differences between groups was 
calculated by Student’s t-test. P values ,0.05 were considered 
statistically significant.
Results
Cytotoxic effects of oridonin 
nanosuspension and free  
oridonin on PANC-1 cells
To determine the cytotoxicity effects of oridonin nanosus-
pension and free oridonin on PANC-1 cells, the cells were 
cultured with different concentrations for different time 
periods and the cytotoxic effect was measured by MTT 
assay.   Oridonin nanosuspension and free oridonin induced 
cell death in a dose- and time-dependent manner. As shown 
in Figure 2, the inhibitory rate of oridonin   nanosuspension 
is significantly higher than that of free oridonin at the 
  concentrations of 3.14, 6.25, and 12.5 µmol/L.
Oridonin nanosuspension  
and free oridonin induce morphologic 
changes and apoptotic cell death  
in PANC-1 cells
As shown in Figure 3A, after the cells were exposed to ori-
donin, marked morphologic changes were observed. Cells 
underwent contraction and became round in shape. But there 
were no obvious differences in morphology between free 
oridonin and its formulation.
To confirm whether oridonin-induced cell death in PANC-1 
was caused by apoptosis, PI and Hoechst 33342 staining were 
carried out. PI is membrane impermeant, generally excluded 
from viable cells, and is commonly used for identifying dead 
cells in a population. As shown in   Figure 3B, the red cell 
nuclei represent the middle–late apoptotic or necrotic cells. 
The result showed that compared with the control group, the 
stained cells increased in a dose-dependent manner, which 
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means that oridonin nanosuspension and free oridonin could 
induce PANC-1 cell death.
Hoechst 33342 staining of the cell nuclei further confirmed 
that oridonin nanosuspension and free oridonin induced apopto-
sis in PANC-1 cells. The major findings are showed by arrows in 
Figure 3C. In the control group, the nuclei of the PANC-1 cells 
were round and homogeneously stained, but the cells treated 
with oridonin and its formulation showed cell shrinkage, chro-
matin condensation, and cell membrane blebbing.
Treatment with oridonin nanosuspension 
or free oridonin leads to apoptosis  
of PANC-1 cells
Flow cytometric analysis with annexin V-FITC and PI 
staining was undertaken to determine the effect of oridonin 
  nanosuspension and free oridonin on PANC-1 apoptosis. 
  Figure 4 shows the distribution of cell populations after 
24 hours of treatment with oridonin nanosuspension or free 
oridonin, and the lower right quadrant represents early apop-
totic cells. The results showed that the early apoptotic rates 
of cells were 1.5% (control), 4.0% m and 15.4% (5 µmol/L 
and 10 µmol/L free oridonin), 5.1%, and 20.9% (5 µmol/L 
and 10 µmol/L oridonin nanosuspension), respectively. These 
statistics indicate that oridonin nanosuspension and free ori-
donin both induced PANC-1 apoptosis in a dose-dependent 
manner. Oridonin nanosuspension at a concentration of 
10 µmol/L had a more significant apoptosis-inducing effect 
compared with free oridonin.
Oridonin nanosuspension and free 
oridonin induces G2/M phase cell cycle 
arrest in PANC-1 cells
To determine whether oridonin nanosuspension and free 
oridonin regulate cell cycle progression in PANC-1 cells, the 
cells were treated for 24 hours and 48 hours with different con-
centrations of oridonin nanosuspension or free oridonin (5, 10, 
and 15 µmol/L), and the DNA was stained with PI, followed 
by fluorescence activated cell sorting analysis. As shown in 
Figure 5A, compared with the control, the percentage of cells 
increased in the G2/M phase in a dose-dependent manner, but 
did not change in the S phase. Cells treated with 10 µmol/L and 
15 µmol/L oridonin nanosuspension for 24 hours had a higher 
fraction of G2/M phase cells (34.6% and 46.7%) compared 
with that of cells treated with free oridonin (23% and 32.9%). 
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Figure 2 Cytotoxic effects of oridonin nanosuspension and free oridonin on PANC-1 cells. 
Notes: Data are mean ± standard deviation (n = 3), *P , 0.05, **P , 0.01, and ***P , 0.001 vs control group, #P , 0.05, ##P , 0.01, ###P , 0.001 vs the same dose of free 
oridonin group. 
Abbreviation: ORI, oridonin.
Figure  3  Oridonin  nanosuspension-induced  and  free  oridonin-induced  morphologic  changes  of  PANC-1  cells.  (A)  Cellular  morphology  was  examined  in  the 
presence of different doses of oridonin nanosuspension and free oridonin. Nuclear morphology was determined using (B) propidium iodide staining and (C) hoechst 
33342 staining.
Abbreviation: ORI, oridonin.
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Figure 2 Cytotoxic effects of oridonin nanosuspension and free oridonin on PANC-1 cells. 
Notes: Data are mean ± standard deviation (n = 3), *P , 0.05, **P , 0.01, and ***P , 0.001 vs control group, #P , 0.05, ##P , 0.01, ###P , 0.001 vs the same dose of free 
oridonin group. 
Abbreviation: ORI, oridonin.
Figure  3  Oridonin  nanosuspension-induced  and  free  oridonin-induced  morphologic  changes  of  PANC-1  cells.  (A)  Cellular  morphology  was  examined  in  the 
presence of different doses of oridonin nanosuspension and free oridonin. Nuclear morphology was determined using (B) propidium iodide staining and (C) hoechst 
33342 staining.
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Figure 4 The effect of oridonin nanosuspension and free oridonin on PANC-1 cell apoptosis was measured by annexin V-fluorescein isothiocyanate/propidium iodide 
staining. The early apoptotic cells stained by annexin-V-fluorescein isothiocyanate are located in the lower right quadrant.
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Figure 6 The effect of oridonin nanosuspension and free oridonin on apoptosis-related proteins in PANC-1 cells. (A) The expression of Bax, and Bcl-2. (B) The expression 
of pro-caspase-3. (C) The effect of free oridonin and oridonin nanosuspension on caspase-3 activity. 
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(Continued on next page)
However, after 48 hours’ treatment, the fractions of cells in the 
S phase and the G2/M phase both increased (Figure 5B).
Involvement of Bax, Bcl-2, and caspase-3  
in oridonin nanosuspension-induced  
and free oridonin-induced cell death
It is known that the Bcl-2 family of proteins play important 
roles in either inhibition or promotion of   apoptotic cell death. 
To confirm whether the Bcl-2 family of proteins are involved 
in oridonin nanosuspension-induced or free   oridonin-induced 
PANC-1 cell death, we examined the expression of Bcl-2 
family proteins Bcl-2 and Bax by Western blot analysis. After 
treatment with oridonin nanosuspension or free oridonin for 
different time periods, the expression of Bax was upregulated, 
whereas there were no obvious changes in expression of Bcl-2 
(Figure 6A).
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To further explore the apoptotic signaling pathway of 
oridonin-induced cell death, we examined the expression of 
pro-caspase3 (Figure 6B) and caspase-3 activity (Figure 6C). 
Oridonin nanosuspension and free oridonin treatment of 
PANC-1 cells both stimulated activity of caspase-3.
Effects of oridonin nanosuspension and 
free oridonin on the expression of G2/M 
phase cell cycle-related proteins
To examine whether the cell cycle arrest is associated with 
the expression of cell cycle regulatory proteins, the   levels 
of G2/M regulatory proteins were assessed. As shown in 
Figure 7 the expression of cyclin B1 and p-cdc2 (T161) was 
suppressed in a time-dependent manner. However, neither 
oridonin nanosuspension nor free oridonin had an effect on 
the expression level of cdc2 protein.
Discussion
Many compounds extracted from Rabdosia rubescens have 
been proved to have antitumor activity against a number 
of cancer cells, and oridonin is one of the most effective 
  derivatives. Although a previous study had shown that 
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oridonin had considerable antiproliferation effects on some 
kinds of   cancer, few studies of the anticancer activity of 
oridonin nanosuspension and free oridonin on human 
pancreatic   cancer have been undertaken.4 In our study, we 
demonstrated that oridonin nanosuspension and free oridonin 
could both inhibit the growth of human pancreatic cancer cell 
line PANC-1 by inducing cell cycle arrest and apoptosis, and 
oridonin nanosuspension exhibited increased cytotoxic effect. 
Our results showed that the inhibitory rate of oridonin 
nanosuspension is significantly higher than that of free 
oridonin at the concentrations of 3.14, 6.25, and 12.5 µmol/L, 
while at higher concentrations, there was no statistical 
difference in cytoxicity. A previous study showed that ori-
donin nanosuspension, possessing a significantly increased 
solubility and dissolution rate than free oridonin, could 
markedly induce oridonin molecular concentration around 
the cells.15 Apart from this, the small size of nanosuspension 
may facilitate its adhesion to the cells and improve the inter-
actions between the cells and drugs. Moreover, it is generally 
considered that nanoparticles can be nonspecically internal-
ized into cells via endocytosis or   phagocytosis.16 Therefore, 
the oridonin nanosuspension was more effective at a lower 
concentration.
Observation  of  morphologic  changes  through 
Hoechst 33342 and PI staining and annexin V-FITC/
PI   staining   suggested oridonin nanosuspension and free 
  oridonin-induced cell apoptosis of PANC-1 cells, between 
which the former was more conspicuous. Apoptosis is 
regulated by a complex network of molecules, and involves 
the expression changes of distinct pro-apoptotic and anti-
apoptotic proteins. Bcl-2 family members are character-
ized by containing at least one of four Bcl-2 homology 
domains (BH1–BH4). Proteins of the Bcl-2 family such as 
Bax and bcl-2 have been shown to play an essential role in 
cell apoptosis.17 Bax can bind Bcl-2 and the heterodimer 
provides protection against apoptosis. Therefore, the Bcl-2/
Bax ratio is important in apoptosis and its decline induces 
apoptosis.18 Our present results showed that after oridonin 
administration, the expression of Bax gradually increased 
with time, whereas Bcl-2 protein expression did not   
change.
Caspases, a family of cysteases, play an important role 
in regulating apoptotic signal transmission, and can be 
divided into two groups including upstream caspases such 
as caspase-2, -8, and -10, and downstream caspases such as 
caspase-3, -6, and -7. Caspase-3 is one of the most impor-
tant “effector” caspases, and is capable of cleaving many 
important cellular substrates.19–21 In this study, we examined 
the expression of pro-caspase3 and caspase-3 activity, and 
the result suggested that caspase-3 was involved in oridonin 
nanosuspension-induced and free oridonin-induced PANC-1 
cell apoptosis.
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Figure 7 The expression of cyclin B1, cdc2, and p-cdc2 (T161) in PANC-1 cells detected by Western blot analysis.
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Previous studies showed that Bax/Bcl-2 acted in 
  mitochondria to cause the cytochrome c release into 
cytoplasm, and then cytochrome c, apoptotic protease 
activating factor-1, and procaspase-9 formed a complex 
leading to caspase-9 activation. Activated caspase-9 cleaved 
caspase-3 proenzyme, and then activated caspase-3 acted 
on its substrates which are important for cell survival.22,23 
When compared with our results, it can be deduced that this 
signal pathway may be involved in oridonin nanosuspension-
induced and free oridonin-induced PANC-1 cell apoptosis.
As suggested by our data from cell cycle analysis, 
oridonin nanosuspension and free oridonin both arrested 
PANC-1 cells in the G2/M phase, and we also demonstrated 
that the expression levels of cyclin B1 and p-cdc2 (T161) 
decreased significantly after treatment in which oridonin 
nanosuspension had more significant effect due to its smaller 
size.24,25 It is well known that the progression through various 
phases of cell cycle is a tightly regulated process involving 
the activities of various cyclins and cyclin-dependent kinases, 
which are specific for different cell cycle phases.26 Cyclin B1 
and cdc2, which are the master regulators in cell prolifera-
tion, play an important role in the G2/M phase transition of 
mitosis in cell proliferation. The inactivity of cyclin B1 and 
cdc2 resulted in cell cycle arrest in the G2/M phase.27,28
In summary, we demonstrated that both oridonin nanosus-
pension and free oridonin have significant antiproliferation 
effects on PANC-1 cells, and the effects were intensified by 
oridonin nanosuspension. However, oridonin nanosuspen-
sion did not change the antiproliferation mechanism of free 
oridonin. They both induced G2/M phase cell cycle arrest and 
apoptosis in PANC-1 cells. Our results showed that cyclin B1 
and cdc2 were involved in oridonin-induced cell cycle arrest, 
and oridonin-induced PANC-1 cell apoptosis was mediated 
by a decreased Bcl-2/Bax ratio and activation of caspase-3.
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